In his bookTiHKAL (Tryptamines I Have Known and Loved),Alexander Shulgin lists the dose of 5-MeO-MiPT as 4 to 6mgorally and 12 to 20mgsmoked.[1][6] A widerrecreational dose range of 0.5 to 20mg or more orally has also been reported however.[4][16][5] Oral doses of 1 to 3mg have been described as light, 3 to 8mg as common or moderate, and 8 to 12mg as strong.[5] Itsonset of action when taken orally is described as very rapid, occurring within 15 to 45minutes, peak effects appear to occur after around 1 to 2hours, and itsduration as 4 to 6hours.[1][6] However, other sources state its duration as 3 to 8hours.[4][5] Aclinical trial confirmed that 5-MeO-MiPT has an onset of about 30minutes and that peak effects occur after about 1.5 to 2hours.[3] Its duration smoked is said to be 2 to 5hours.[6]
5-MeO-MiPT has been described as having unique and unusual effects relative to other psychedelic tryptamines.[1][4][7] The effects of 5-MeO-MiPT differ depending on whether it is taken orally or smoked and are highlydose-dependent.[1][4] When taken orally at relatively low doses like 4 to 6mg, it is usually described as not producingpsychedelic visuals or relatedsensory effects and as producing only hints oftime dilation.[1][4] However, it is said to produce astoned state that includes an ease ofinterpretive fantasy,dream-likeperception, intenseconceptual thought andphilosophical thinking, and mild perceptual effects like altereddepth perception, minor wave pattern in peripheral vision, and slightly enhanced auditory acuity.[1] Moreover, the drug is described as producingstimulation, greatly enhanced tactile sensation anderoticism, enhancedmusic appreciation,tingling,shakes, and mildmotor impairment.[1][4] Its head space is described as relatively "shallow", less confusing, and more easily tolerated compared to classical psychedelics.[4] Its effects have been described by users variably as both pleasant and negative.[1][4]
When smoked, 5-MeO-MiPT is described as having effects similar in many regards to those of5-MeO-DMT.[1] These effects of smoked 5-MeO-MiPT include a powerfulrush (but less intense than 5-MeO-DMT), loss ofcoherent thought, not much in the way of visuals,closed-eye visuals of moving and colored geometric patterns, intense waves ofmental imagery of emotionally infusedmemories, impressive recall of early memories, intensedepersonalization or disorientation of the normal sense of being a person in a body, loss of immediate contact with surroundings,emotional lability includinglaughing,crying, and vocal outbursts,groaning, writhing, shaking around, and generaldisorientation.[1] It is described as having a very rapid onset, with the peak phase lasting less than 30minutes and waves continuing for up to a few hours.[1] It was described by one user as feeling like a hybrid betweendiethyltryptamine (DET) and 5-MeO-DMT.[1]
5-MeO-MiPT is also known by its nickname "Moxy"[4] and is closely related both in terms ofchemical structure and effects to5-MeO-DiPT (also known as "Foxy Methoxy").[1][7] These two serotonergic tryptamines at low doses have been described as veryaphrodisiac and much morestimulant-like andparty drugs than classical psychedelics.[7] However, they have been described as not innately aphrodisiac, but instead as enhancing tactile sensation in a way that lends itself tosex.[7]Matthew Baggott has described 5-MeO-MiPT as having someMDMA-likeentactogenic effects at low doses, including tactile enhancement and feelings ofempathy,intimacy, and closeness with others, and as producing classical psychedelic effects at higher doses.[17]
Mindstate Design Labs has described 5-MeO-MiPT as the "least psychedelic psychedelic that's psychoactive".[3] It is described as being quite psychoactive, but as lacking "hallucinations" and as not producing "mind-bending trips".[3] The drug was assessed at five different doses byoral administration in aphase 1clinical trial in 47individuals.[3] Its effects included heightened emotions, associative thinking, enhanced imagination, and perceptual effects such as brighter colors.[3] However, there were no hallucinations,self-disintegration,oceanic boundlessness, or other typical features ofpsychedelic experiences.[3] Itsonset was 30minutes and its peak of effects was 1.5 to 2hours.[3] Mindstate Design Labs has hypothesized that a mild psychedelic experience, as with 5-MeO-MiPT, could still provide therapeutic benefits without overthallucinogenic effects.[3]
In addition to its use on its own, 5-MeO-MiPT, along with the related tryptamine psychedelic4-HO-MET, is employed as a component of the MDMA-mimickingBorax combo.[4][18][19][20]
Adverse effects of 5-MeO-MiPT includeloss of appetite andinsomnia.[1] Low-dose 5-MeO-MiPT did not cause any serious histopathological effects on the liver, kidney, and brain. High doses induce apoptotic cell death through caspase activity especially in some parts of the organs.[21] There is no known documentation of death attributed to the use of 5-MeO-MiPT alone.[4]
In one humancase report 5-MeO-MiPT concentrations were measured at 160ng/mL in blood and 3,380ng/mL inurine samples collected approximately one and two hours post-exposure, respectively.[31]
In vivo analysis of forensic case sample identified five phase I metabolites in blood and seven in urine. The metabolites detected in both blood and urine included5-MeO-NiPT,5-HO-MiPT, 5-MeO-MiPT-N-oxide, and HO-5-MeO-MiPT.[31] Two additionalphase II metabolites (glucuronides) were found in mice andin vitro models, but not in human urine sample.[31][33][34]
In silico ADMET predicted the compound to be asubstrate but not an inhibitor for theCYP1A2 andCYP2C9enzymes, and a substrate forCYP2A6 andCYP2B6.[32] Additionally, the compound is predicted to be both substrate and inhibitor for theCYP2D6.[32]
Detection of multiple metabolites in human urine sample two hours post-exposure, along with measurable blood concentrations at one hour, suggest relatively rapid metabolism andelimination.[31] Renal excretion is likely a major route of elimination.[31]
5-MeO-MiPT, also known as 5-methoxy-N-methyl-N-isopropyltryptamine, is in a class of compounds commonly known astryptamines, and is theN-methyl-N-isopropylhomologue of5-MeO-DMT.[1]
The legal status of 5-MeO-MiPT differs internationally. It is not scheduled inCanada but is illegal if is sold for human consumption or recreational use ,[37] and inLuxembourg it is not listed among prohibited substances, making it not illegal but a legal gray area there.[38] In theUnited States, it is unscheduled at the federal level,[39] but may be treated as an analog of5-MeO-DiPT under theFederal Analog Act therefore if is sold for human consumption and not for medical or scientific uses is illegal and persecuted. At the state level, "5-Methoxy-N-methyl-N-isopropyltryptamine" is classified as a Schedule Icontrolled substance inFlorida, prohibiting its purchase, consumption, sale, or possession.[40]
In other jurisdictions, control is stricter and could be punished by death or life imprisonment its sale for human use. As of September–October 2015, China lists 5-MeO-MiPT as a controlled substance.[41] Finland includes it in its decree banning certain psychoactive substances from the consumer market.[42] In theUnited Kingdom, it is classified as a Class A drug along with most ethers of ring-hydroxy tryptamines.[citation needed]
5-MeO-MiPT, under the developmental code name MSD-001, is being developed for the treatment ofpsychiatric disorders.[3][12][13][14][15] It is under development specifically by Mindstate Design Labs.[3][12][13][14][15] As of October 2025, the drug is inphase 1clinical trials in theUnited States andEuropean Union.[3][12][13][43][44][45] A phase 1 trial was completed in July 2025.[3][12] Mindstate Design Labs has developed anartificial intelligence (AI) platform known as Osmanthus to analyzetrip reports in order to identify relationships betweenreceptor interactions andpsychoactive effects.[46][47][48][49] Other research of this sort has also been conducted and published by other groups.[50] Mindstate Design Labs's platform has processed 70,000online trip reports and led to the selection of 5-MeO-MiPT for development.[3][46][47][48][49] According to its developer, 5-MeO-MiPT is intended as a "neutral base compound" with mild effects on its own for use as a sort of "psychedelic tofu" in combination with other drugs to precisely modulate serotonin receptors and create various uniquealtered states of consciousness.[3][46][47][48][49]
^abcdMalaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA (December 2020)."Toxicology and Analysis of Psychoactive Tryptamines".International Journal of Molecular Sciences.21 (23): 9279.doi:10.3390/ijms21239279.PMC7730282.PMID33291798.5-Methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT): 5-MeO-MiPT or "moxy" was marketed as a "plant fertilizer." Oral doses ranged from 1–3 mg (light), 3–8 mg (common) and 8–12 mg (strong), with typical 10–20 mg doses if inhaled [22,103]. The principal effects lasted 3–7 h and included a general heightening of awareness, mild euphoria, psychedelic visual effects, such as enhanced colors but also anxiety, nausea, confusion and paranoia. Repke et al. studied if the effects of the drug would differ depending upon the route of administration [104]. If ingested the effects were stimulating, with visual hallucinations prevailing. 5-MeO-MiPT metabolism studied by LC-HRMS/MS identified six phase I metabolites following N-demethylation, O-demethylation, demethylation and hydroxylation and N-oxide formation and hydroxylation of the parent compound and N-O-bis-demethylation of the metabolite 5-OH-MiPT [105].
^abcdefgPalamar JJ, Acosta P (January 2020)."A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines".Human Psychopharmacology.35 (1) e2719.doi:10.1002/hup.2719.PMC6995261.PMID31909513.5-Meo-DIPT, Foxy, or Moxy (5-Meo-MIPT) are tryptamines that are distinct. A lot of people I know that like them think they're very aphrodisiac and much more stimulant and a party drug. My opinion on 5-MeO-MIPT is that it was a very sexual chemical … it feels good to touch things, and that sort of sensation certainly lends itself to sex but I wouldn't call it innately an aphrodisiac.
^abcdRickli A, Moning OD, Hoener MC, Liechti ME (August 2016). "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens".European Neuropsychopharmacology.26 (8):1327–1337.doi:10.1016/j.euroneuro.2016.05.001.PMID27216487.S2CID6685927.
^"Borax Combo (Synonyms: Blue Bliss)".naddi.org. National Association of Drug Diversion Investigators (NADDI). 14 December 2022. Retrieved21 November 2024.
^abcNagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain".European Journal of Pharmacology.559 (2–3):132–137.doi:10.1016/j.ejphar.2006.11.075.PMID17223101.
^abcGlatfelter GC, Clark AA, Cavalco NG, Landavazo A, Partilla JS, Naeem M, et al. (December 2024). "Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice".ACS Chemical Neuroscience.15 (24):4458–4477.doi:10.1021/acschemneuro.4c00513.PMID39636099.
^Compton DM, Dietrich KL, Selinger MC, Testa EK (May 2011). "5-methoxy-N,N-di(iso)propyltryptamine hydrochloride (Foxy)-induced cognitive deficits in rat after exposure in adolescence".Physiology & Behavior.103 (2):203–209.doi:10.1016/j.physbeh.2011.01.021.PMID21295050.
^abcdefghGrafinger KE, Hädener M, König S, Weinmann W (March 2018). "Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples".Drug Testing and Analysis.10 (3):562–574.doi:10.1002/dta.2245.PMID28677880.
^abcWang Y, Zhong C, Chen J, Meng L (April 2024). "Biotransformation of 5-methoxy-N-isopropyl-N-methyltryptamine by zebrafish and human liver microsome with high-resolution mass spectrometry".Journal of Pharmaceutical and Biomedical Analysis.241 115987.doi:10.1016/j.jpba.2024.115987.PMID38280235.
^Fabregat-Safont D, Barneo-Muñoz M, Martinez-Garcia F, Sancho JV, Hernández F, Ibáñez M (July 2017). "Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice".Journal of Chromatography. A.1508:95–105.doi:10.1016/j.chroma.2017.06.010.PMID28602505.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" [Notice on Printing and Distributing the "Measures for the Scheduling of Non-Pharmaceutical Narcotic Drugs and Psychotropic Substances"] (in Chinese). China Food and Drug Administration. 27 September 2015. Archived fromthe original on 1 October 2015. Retrieved1 October 2015.
^abcDimitropoulos S (12 June 2025)."Science Has a Powerful New Tool to Unlock the Mysteries of Consciousness—And Even Help You Reach Transcendence".Popular Mechanics. Retrieved7 August 2025.Their first proprietary compound, MOXY, currently in a 52-person Phase I trial, is designed to be just that, says DiNardo: "A sort of 'psychedelic tofu,' a drug that allows moderate cognitive flexibility, but isn't likely to cause awe or ego dissolution." In other words, MOXY acts as a neutral base that's mild on its own, but intended to combine with other compounds to produce fine-tuned mental states.
